Beijing Wantai Biological Pharmacy Enterprise Co Ltd
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. research, develops, produces, and sells in vitro diagnostic reagents and instruments, and vaccines in China and internationally. It operates through Diagnostics Division and Vaccine Division segments. The company offers chemiluminescence detection, biochemical, hepatitis B core antibody detection, and HIV reagents; rapid urine tests for hepa… Read more
Beijing Wantai Biological Pharmacy Enterprise Co Ltd (603392) - Total Assets
Latest total assets as of September 2025: CN¥14.37 Billion CNY
Based on the latest financial reports, Beijing Wantai Biological Pharmacy Enterprise Co Ltd (603392) holds total assets worth CN¥14.37 Billion CNY as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Beijing Wantai Biological Pharmacy Enterprise Co Ltd - Total Assets Trend (2013–2024)
This chart illustrates how Beijing Wantai Biological Pharmacy Enterprise Co Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Beijing Wantai Biological Pharmacy Enterprise Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Beijing Wantai Biological Pharmacy Enterprise Co Ltd's total assets of CN¥14.37 Billion consist of 57.0% current assets and 43.0% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 16.3% |
| Accounts Receivable | CN¥2.08 Billion | 14.1% |
| Inventory | CN¥863.19 Million | 5.9% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥712.86 Million | 4.9% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2013–2024)
This chart illustrates how Beijing Wantai Biological Pharmacy Enterprise Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Beijing Wantai Biological Pharmacy Enterprise Co Ltd's current assets represent 57.0% of total assets in 2024, a decrease from 59.9% in 2013.
- Cash Position: Cash and equivalents constituted 16.3% of total assets in 2024, down from 22.0% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 4.0% of total assets, a decrease from 9.0% in 2013.
- Asset Diversification: The largest asset category is accounts receivable at 14.1% of total assets.
Beijing Wantai Biological Pharmacy Enterprise Co Ltd Competitors by Total Assets
Key competitors of Beijing Wantai Biological Pharmacy Enterprise Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Beijing Wantai Biological Pharmacy Enterprise Co Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Beijing Wantai Biological Pharmacy Enterprise Co Ltd generates 0.15x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Moderate ROA - For every $100 in assets, Beijing Wantai Biological Pharmacy Enterprise Co Ltd generates $ 0.72 in net profit.
Beijing Wantai Biological Pharmacy Enterprise Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.26 | 4.61 | 2.39 |
| Quick Ratio | 3.82 | 4.18 | 1.90 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥6.12 Billion | CN¥ 7.04 Billion | CN¥ 1.15 Billion |
Beijing Wantai Biological Pharmacy Enterprise Co Ltd - Advanced Valuation Insights
This section examines the relationship between Beijing Wantai Biological Pharmacy Enterprise Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.20 |
| Latest Market Cap to Assets Ratio | 0.09 |
| Asset Growth Rate (YoY) | -6.5% |
| Total Assets | CN¥14.69 Billion |
| Market Capitalization | $1.39 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Beijing Wantai Biological Pharmacy Enterprise Co Ltd's assets below their book value (0.09 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Beijing Wantai Biological Pharmacy Enterprise Co Ltd's assets decreased by 6.5% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Beijing Wantai Biological Pharmacy Enterprise Co Ltd (2013–2024)
The table below shows the annual total assets of Beijing Wantai Biological Pharmacy Enterprise Co Ltd from 2013 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥14.69 Billion | -6.53% |
| 2023-12-31 | CN¥15.71 Billion | -3.17% |
| 2022-12-31 | CN¥16.23 Billion | +130.34% |
| 2021-12-31 | CN¥7.05 Billion | +101.10% |
| 2020-12-31 | CN¥3.50 Billion | +61.84% |
| 2019-12-31 | CN¥2.16 Billion | +19.30% |
| 2018-12-31 | CN¥1.81 Billion | +9.60% |
| 2017-12-31 | CN¥1.66 Billion | +13.84% |
| 2016-12-31 | CN¥1.45 Billion | +32.03% |
| 2015-12-31 | CN¥1.10 Billion | +36.76% |
| 2014-12-31 | CN¥805.50 Million | +32.71% |
| 2013-12-31 | CN¥606.98 Million | -- |